BioDelivery Awaits Final FDA Word – Analyst Blog
Source: http://www.zacks.com/stock/news/21062/BioDelivery+Awaits+Final+FDA+Word+-+Analyst+BlogPosted on Monday, June 15th, 2009 | In Market Commentary, Stocks to Watch
This morning, BioDelivery Sciences International (BDSI) announced that it has reached an agreement with the U.S. Food and Drug Administration’s (FDA) Division of Anesthesia, Analgesia and Rheumatology Product on all aspects of the company’s New Drug Application (NDA) on Onsolis.
The agreement includes the Risk Evaluation and Mitigation Strategy (REMS), which was the previous hurdle to approval and the key reason for the complete response letter received in August 2008. BDSI refilled the NDA in December 2008 with the updated REMS requirement.
We expect final FDA action in the next few weeks. Coming to an agreement with the reviewing division and the review team on all aspects of the NDA, including the REMS, clearly bodes well for final approval of the drug.
Approval will be a transformational event for BDSI. Not only will it bring about a $30 million milestone payment from worldwide commercialization partner, Meda AB, but BDSI will also receive double-digit royalties (we estimate 20%) on sales of Onsolis upon launch.
The breakthrough cancer pain market is highly competitive, and there are several formulations of fentanyl already on the market, with several more in late-stage development, but we believe that BDSI’s BEMA technology offers significant advantages over existing delivery technologies and could allow for Onsolis to be at least a $250 million peak sales drug.
The company plans to host a conference call at 11AM EST today (June 15, 2009) to discuss the NDA status of Onsolis.
Read the full analyst report on “BDSI”
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
- Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
- Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
- Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
- GameStop Meets Expectations - Analyst Blog - November 20th, 2009
Analgesia and Rheumatology Product;, BEMA ;, BEMA technology;, BioDelivery Sciences International;, Blog, breakthrough cancer pain;, Conference Call, December;, Division of Anesthesia, existing delivery ;, existing delivery technologies;, Fda, Market Commentary, Meda Ab, Stocks to Watch, U.S. Food and Drug Administration, USD, Zacks Market Commentaries
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.